Last reviewed · How we verify

NCT02728791: CONDUCT

Comparison of Allows Measurement of Cardiac Output Between Clearsight System and Transpulmonary Thermodilution

Status unknown Last updated 24 January 2018
What this trial tests

trial in Shock in 40 participants. Status unknown.

Timeline
10 May 2016
Primary endpoint
10 December 2018
10 December 2018

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date10 May 2016
Primary completion10 December 2018
Estimated completion10 December 2018
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

Adults 18 to 80, any sex, with Shock or Cardiac Output, Low. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Correlation study between the data provided by two measurement systems, trans- pulmonary thermodilution and ClearSight © (non invasive), to determine the interest in routine use (cardiac output, cardiac index, stroke volume and blood pressure).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Shock

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02728791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing